Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells.

Cancer cell - 1 Mar 2003

Dolma Sonam, Lessnick Stephen L, Hahn William C, Stockwell Brent R

Abstract excerpt

We used synthetic lethal high-throughput screening to interrogate 23,550 compounds for their ability to kill engineered tumorigenic cells but not their isogenic normal cell counterparts. We identified known and novel compounds with genotype-selective activity, including doxorubicin, daunorubicin, mitoxantrone, camptothecin, sangivamycin, echinomycin, bouvardin, NSC146109, and a novel compound that we named...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Transformation, Viral
Share to Drug Screening Assays, Antitumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluoresceins

Share to Fluorescent Dyes

Share to Genetic Engineering

Share to Inhibitory Concentration 50

Share to Oncogene Proteins

Share to Retroviridae

Source

Identifiers

PMID: 12676586
DOI: 10.1016/s1535-6108(03)00050-3

Genes

HRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells.PMID 12676586Read ↗

Desperately seeking genotype-selective anticancer agents.Semantic proximity Read ↗

Development of small-molecule probes that selectively kill cells induced to express mutant RAS.Semantic proximity Read ↗

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.Semantic proximity Read ↗

Development of synthetic lethality anticancer therapeutics.Semantic proximity Read ↗

Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agentsSemantic proximity Read ↗

Selective killing of cancer cells by a small molecule targeting the stress response to ROS.Semantic proximity Read ↗

The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoningSemantic proximity Read ↗

Heterogeneous therapy-resistant cancer cells have distinct and exploitable drug sensitivity profilesSemantic proximity Read ↗

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses.Semantic proximity Read ↗

Alkylation Sensitivity Screens Reveal a Conserved Cross-species FunctionomeSemantic proximity Read ↗

Cell-based assays for identification of novel double-strand break-inducing agents.Semantic proximity Read ↗

Genome-wide screen for anticancer drug resistance in haploid human embryonic stem cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.